Medical Cate Technologies Inc. (OTCID:MDCE) Melanoma Scan Beta Targets the Visual Race Against Time in America's Deadliest Common Skin Cancer
Medical Care Technologies (OTCID: MDCE) publicized continued development of its MDCE Melanoma Scan Beta, an AI-assisted imaging and body-map application that helps users catalog skin images and review visible changes over time. The platform remains in beta-stage development and has not received regulatory clearance; the release states it is not intended to diagnose, treat, cure, or prevent any disease and is not a substitute for professional medical evaluation.
Key figures
- Expected melanoma deaths 2026
- 8510
- Melanoma share of skin cancers
- about 1%
- Five year relative survival distant
- 36%
- Five year relative survival localized
- greater than 99%
- Expected new invasive melanoma cases 2026
- 112000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.